stockportfolio.pro
Stocks / SPRY vs USPH
SPRY vs USPH
ARS Pharmaceuticals, Inc. and U.S. Physical Therapy, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| ARS Pharmaceuticals, Inc. (SPRY) | U.S. Physical Therapy, Inc. (USPH) | |
|---|---|---|
| Market cap | $0.9B | $0.9B |
| Revenue (latest FY) | $84.28M | $780.99M |
| Net income (latest FY) | $-171.30M | $39.58M |
| Revenue growth (5y CAGR) | — | 13.0% |
| Net margin | -203.3% | 5.1% |
| Return on equity | -149.9% | 8.3% |
| P/E ratio | — | 124.5 |
| Dividend yield | — | 2.9% |
| Profitable years (of last 10) | 1 | 10 |
| Positive free cash flow | No | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open SPRY — free Open USPH — freeFrequently asked questions
Which is bigger, SPRY or USPH?
U.S. Physical Therapy, Inc. is larger by market capitalization — $0.9B versus $0.9B.
Which grows faster, SPRY or USPH?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.